Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHESTNUT: ALXN1850 vs asfotase alfa in pediatric hypophosphatasia previously treated with asfotase alfa
jRCT2051230131Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of efzimfotase alfa in hypophosphatasia (HPP) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Number of participants with treatment-emergent adverse events (TEAEs). Started Apr 2024; status: active, not recruiting.
02
Drugs
efzimfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on jRCT2051230131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230131.